Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Accumulated Expenses: 2016-2025

Historic Accumulated Expenses for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $51.5 million.

  • Collegium Pharmaceutical's Accumulated Expenses rose 8.13% to $51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.5 million, marking a year-over-year increase of 8.13%. This contributed to the annual value of $72.1 million for FY2024, which is 91.97% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Accumulated Expenses stood at $51.5 million, which was down 13.41% from $59.4 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Accumulated Expenses registered a high of $72.1 million during Q4 2024, and its lowest value of $16.9 million during Q1 2021.
  • For the 3-year period, Collegium Pharmaceutical's Accumulated Expenses averaged around $44.6 million, with its median value being $38.7 million (2024).
  • Per our database at Business Quant, Collegium Pharmaceutical's Accumulated Expenses surged by 143.09% in 2022 and then slumped by 40.51% in 2023.
  • Collegium Pharmaceutical's Accumulated Expenses (Quarterly) stood at $29.2 million in 2021, then rose by 23.67% to $36.1 million in 2022, then rose by 3.99% to $37.6 million in 2023, then spiked by 91.97% to $72.1 million in 2024, then rose by 8.13% to $51.5 million in 2025.
  • Its Accumulated Expenses was $51.5 million in Q3 2025, compared to $59.4 million in Q2 2025 and $53.7 million in Q1 2025.